ANA restores IL-1/IL-1Ra balance by inhibiting IL-1 activity by competitively binding to IL-1R and has been approved by the FDA for the treatment of RA, early-onset multisystem inflammatory disease (NOMID) in children and adults (202, 203). Here, IL1A is linked to CINCA syndrome.